NSD2 and plasma cell myeloma: This PROTAC inhibited proliferation of KMS11 and H929 multiple myeloma cells much more effectively than UNC6934, indicating that pharmacological degradation of NSD2 and IKZF1/3 is a superior therapeutic strategy to pharmacological antagonism of the NSD2-PWWP1 and chromatin PPIs.